Rabbit antithymocyte globulin (Thymoglobulin(R)) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients
Open Access
- 16 July 2012
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (1) , 23-30
Abstract
Rabbit antithymocyte globulin-Genzyme™ is used to prevent graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Common disadvantages of treatment are infectious complications. The effects of rabbit antithymocyte globulin-Genzyme™ on thymic function have not been well-studied. Multicolor flow cytometry was used to analyze the kinetics of conventional and regulatory T cells in adult patients treated (n=12) or not treated (n=8) with rabbit antithymocyte globulin-Genzyme™ during the first 6 months after allogeneic hematopoietic stem cell transplantation. Patients treated with rabbit antithymocyte globulin-Genzyme™ had almost undetectable levels of recent thymic emigrants (CD45RA+CD31+) of both conventional and regulatory CD4T cells throughout the 6 months after allogeneic hematopoietic stem cell transplantation whereas CD4+CD45RA-memory T cells were less affected, but their levels were also significantly lower than in patients not treated with rabbit antithymocyte globulin-Genzyme™. In vitro, rabbit antithymocyte globulin-Genzyme™ induced apoptosis and cytolysis of human thymocytes, and its cytotoxic effects were greater than those of rabbit antithymocyte globulin-Fresenius™. Rabbit antithymocyte globulin-Genzyme™ in combination with a conditioning regimen strongly impairs thymic recovery of both conventional and regulatory CD4+ T cells. The sustained depletion of conventional and regulatory CD4+T cells carries a high risk of both infections and graft-versus-host disease. Our data indicate that patients treated with rabbit antithymocyte globulin-Genzyme™ could benefit from thymus-protective therapies and that trials comparing this product with other rabbit antithymocyte globulin preparations or lymphocyte-depleting compounds would be informative.Keywords
This publication has 40 references indexed in Scilit:
- Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignanciesBlood, 2011
- Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantationJournal of Clinical Investigation, 2010
- The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host diseaseJournal of Clinical Investigation, 2010
- Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitroBlood, 2008
- Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host diseaseBlood, 2008
- Imbalance of regulatory T cells in human autoimmune diseasesImmunology, 2006
- CD31+ Naïve Th Cells Are Stable during Six Months Following Kidney Transplantation: Implications for Post-transplant Thymic FunctionAmerican Journal of Transplantation, 2005
- Rapid immune reconstitution following autologous hematopoietic stem cell transplantation in children: a single institution experienceBone Marrow Transplantation, 2003
- Two Subsets of Naive T Helper Cells with Distinct T Cell Receptor Excision Circle Content in Human Adult Peripheral BloodJournal of Experimental Medicine, 2002
- Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitutionThe Lancet, 2000